M&A / Deals Lilly, Gilead lead pharma’s M&A boom BioPharma DiveDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioPharma Dive Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs. Read full story Post navigation Previous: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapyNext: Pulsesight reports positive phase 1 data for PST611 in dry AMD Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026